The supplement, which is only available in Germany, will be available from January 2023.
“We are extremely proud and excited about this new collaboration. SymbioPharm is in the top 3 of the German probiotics market and fathered one of the first probiotic pharmaceuticals globally,” said Grégory Lambert, CEO of TargEDys. “With the team's knowledge of probiotic Enterobacteria, their strong position with doctors, pharmacies, and synergies with probiotics and diagnostics, they are the perfect partner for this highly scientific product.”
HA4597 was first launched in France in 2019, then in Portugal and Italy last year, and this year in Croatia, Turkey and Germany.
As reported by NutraIngredients-USA last year, H. alvei HA4597 may promote satiety by producing the caseinolytic protease B (ClpB) protein, which has been reported to mimic the appetite-reducing alpha-melanocyte-stimulating hormone (alpha-MSH).
These effects were supported by findings from a 12-week supplementation trial in 230 overweight adults, with the probiotic found to significantly increase the proportion of overweight subjects losing at least 3% and even 4% of baseline body weight while following a hypocaloric diet over 12 weeks. Such weight loss levels were described as clinically relevant by the researchers.
Juergen Eck, Co-CEO and CTO of SymbioPharm, commented: “We are very excited to partner with TargEDys and work together on a new era of evidence-based probiotics. With the patent-protected probiotic Hafnia alvei HA4597, its biological mechanism of action and outstanding studies, we can offer an effective solution for the growing problems of obesity and metabolic health.
“As pioneers in microbiome research and medical probiotics, we are proud to now also help shape the introduction of knowledge-based precision probiotics.”